Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 389 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kenalog (Triamcinolone) Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Intraarticular Injections of the Hip and Knee With Triamcinolone Versus Ketorolac: A Randomized Controlled Trial

NCT04441112
View directory record Official record
Conditions
Arthritis Knee, Arthritis of Hip
Interventions
Ketorolac Intraarticular Injection, Triamcinolone Intraarticular Injection
Drug
Lead sponsor
Saint Alphonsus Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 6, 2026, 9:55 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Platelet-Rich Plasma vs Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint

NCT01920373
View directory record Official record
Conditions
Degenerative Joint Disease
Interventions
Group A (corticosteroid injection group), Group B (platelet rich plasma injection group)
Drug · Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 6, 2026, 9:55 AM EDT
Not listed Phase 4 Interventional

Laryngeal Nerve Block for Chronic Cough

NCT05292677
View directory record Official record
Conditions
Laryngeal Nerve Block, Chronic Neurogenic Cough, Laryngeal Hypersensitivity
Interventions
Steroid/Anesthesia Mixture, Placebo
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 6, 2026, 9:55 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

NCT01878786
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
Drug
Lead sponsor
Matthew Cooper
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma

NCT00002681
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
aldesleukin, daclizumab
Biological
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 6, 2026, 9:55 AM EDT
Recruiting Phase 2 Interventional

VEL-101 to Prevent Rejection After Kidney Transplantation

NCT07290777
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Tacrolimus (TAC), VEL-101
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 2 Interventional

Docetaxel, Doxorubicin, and Cyclophosphamide in Treating Women With Stage III Breast Cancer

NCT00004175
View directory record Official record
Conditions
Breast Cancer
Interventions
cyclophosphamide, docetaxel, doxorubicin hydrochloride, conventional surgery
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 6, 2026, 9:55 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Fixation

NCT03995641
View directory record Official record
Conditions
Postoperative Pain, Pelvic Organ Prolapse, Trigger Point Injection, Sacrospinous Ligament Fixation
Interventions
marcaine and kenalog
Drug
Lead sponsor
Kettering Health Network
Other
Eligibility
21 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis

NCT03097315
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 6, 2026, 9:55 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Liver Transplantation With Tregs at UCSF

NCT03654040
View directory record Official record
Conditions
Liver Transplant
Interventions
arTreg, leukapheresis, cyclophosphamide, mesna, everolimus
Biological · Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 6, 2026, 9:55 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis

NCT04160091
View directory record Official record
Conditions
Osteoarthritis of the Shoulder, Adhesive Capsulitis
Interventions
FX006, Normal Saline
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
35 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 6, 2026, 9:55 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Addition of Steroids on Duration of Analgesia

NCT04126824
View directory record Official record
Conditions
Uterine Fibroids, Adenomyosis
Interventions
Triamcinolone, Bupivacaine, Iohexol contrast
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Westwood, Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.

NCT02781818
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Triamcinolone Acetonide 10mg/mL, Triamcinolone Acetonide 40mg/mL, Normal Saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 99 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 6, 2026, 9:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Telephone-Based Coaching Sessions (TAC) to Improve Advance Care Planning Participation in Advanced Cancer Patients and Their Support Person

NCT07141407
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions
Supportive Care, Telephone-Based Intervention, Survey Administration, Educational Intervention
Other · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Everett, Washington • Mount Vernon, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

NCT01476839
View directory record Official record
Conditions
Recurrent Adult Hodgkin Lymphoma
Interventions
basiliximab, carmustine, etoposide, cytarabine, melphalan, pharmacological study, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, yttrium Y 90-labeled basiliximab
Biological · Drug · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 6, 2026, 9:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Epidural Steroid Injection on Bone Mineral Density in Postmenopausal Women

NCT00941473
View directory record Official record
Conditions
To Assess the Changes in Markers of Bone Turnover Over a Six Month Period After Epidural Steroid Inject, To Assess the Changes in Bone Mineral Density
Interventions
Triamcinilone (kenalog)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
55 Years to 80 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of SLN Block for Chronic Cough

NCT04421092
View directory record Official record
Conditions
Cough, Superior Laryngeal Nerve Block, Neurogenic Cough
Interventions
Superior laryngeal nerve block, Injection of placebo (saline), Injection of steroid-lidocaine mixture
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer

NCT00093795
View directory record Official record
Conditions
Breast Cancer
Interventions
Cyclophosphamide, Docetaxel, Gemcitabine, Paclitaxel, Doxorubicin
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
4,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Anchorage, Alaska • Stuart, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Oct 6, 2026, 9:55 AM EDT
Withdrawn Not applicable Interventional

Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients

NCT01612299
View directory record Official record
Conditions
Renal Transplant
Interventions
Zortress® /Everolimus
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 6, 2026, 9:55 AM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Not applicable Interventional Results available

Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia

NCT00928564
View directory record Official record
Conditions
Pelvic Floor Muscle Spasm
Interventions
Pudendal block, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 6, 2026, 9:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Oct 6, 2026, 9:55 AM EDT
Completed Phase 2 Interventional Results available

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

NCT02003365
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
FX006 10 mg, FX006 40 mg, TCA IR 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Paducah, Kentucky • Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 6, 2026, 9:55 AM EDT